August 8, 2020

The Niche

Knoepfler lab stem cell blog

cancer

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More

2 min read

Here are some articles that look especially interesting on stem cells, cancer, and CRISPR. I was just at the SNO meeting in SFO on childhood brain tumors so those are on my mind more. Childhood cerebellar tumours mirror conserved fetal transcriptional programs (Nature) Childhood brain tumors “think” they are building organds in fetuses. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. (Acta Neuropathologica) from Suzy Baker-led team. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and …Read More

3 min read

There’s nothing like stem cell good news and interesting publications to perk one up on a Monday. Enjoy. What recent papers have struck you as exciting? Novel stem cell-based cancer approaches (Part 1) It was exciting when Fate Therapeutics got the first induced pluripotent stem cell (IPSC) IND in the U.S. for their IPSC-derived natural killer cell (NK) product. Now in another milestone the first patient has received the investigational NK therapy at UC San Diego. From UCSD, “After 10 years in remission, Derek Ruff’s cancer …Read More

3 min read

Could potential associated cancer risks claw into CRISPR’s potential? The short answer from both previous and new data is that while CRISPR gene editing impacts the P53 pathway, which is involved in cancer along with having many other functions, this news is neither too surprising nor a fatal flaw, but some caution is warranted. CRISPR is many things including an exciting technology that my own lab uses a lot, but it isn’t and never will be perfect or somehow magical. When this week’s story …Read More